Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Protein S human is a medication used for emergency reversal of coagulation factor deficiency in vitamin K antagonist therapy. Protein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties.
- Mechanism
- Curator reviewed · 6 references
Thrombin converts protein C to activated protein C (APC). Protein S functions as a cofactor for APC and together they proteolytically cleave factor Va and VIIIa. This inhibits the activities of the prothrombinase and tenase complexes respectively and leads to a reduction in thrombin generation. The reduction in thrombin generation suppresses the coagulation cascade preventing additional clotting from occuring. Protein S is suggested to inhibit factors Va and Xa through protein-protein interactions. Protein S is also suggested to inhibit production of factor Xa by the tenase complex by competing for binding to phospholipids via its gamma-carboxyglutamic acid domain.
Protein S is thought to exert an anti-inflammatory effect in addition to its anticoagulant properties. The protein S-C4b-binding protein complex is believed to bind to phosphotidylserines on the cell membranes of apoptotic cells and interact with macrophages, signalling them to phagocytose the cell before it can rupture.
- Primary indication
- Protein S is administered as part of a cocktail containing several other coagulation factors.Curator reviewed · 1 structured indication
- Formula / weight
- 75123.0 Da
- First approval
- Canada, 2007 · United States, 2013
- Also known as
- Protein S · Protein S (human) · Vitamin K-dependent protein S
- Brand names
- Balfaxar
- Beriplex
- Kcentra
- Octaplex
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Protein S human, and which of those have an active Phase 3 trial?